Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


For Some, Oral Insulin’s Allure Persists Despite Hurdles

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The recent release of preliminary Phase III results for Generex Biotechnology Corp.’s buccal spray Oral-lyn put the challenging, but alluring for a few dogged developers, oral insulin development space back in the spotlight momentarily.

You may also be interested in...

Investors Optimistic On FDA Panel For Novo’s Insulin Degludec

Investors appear upbeat about a Nov. 8 FDA advisory committee on Novo Nordisk’s next-generation insulin degludec (Tresiba), despite some concerns on the cardiovascular safety front.

Tackling Oral Insulin: A Niche Development Space

India's Biocon Says Primary Endpoints Set For Oral Insulin May Have Been "Harsh"; Reinforces Goal To Develop Drug With Global Partner

MUMBAI - Indian biotechnology firm Biocon has reinforced its ambitions to bring to market an orally delivered insulin and said it stays firmly on track as it found several "unique and positive" takeaways from its recently concluded Phase III clinical trials in India

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts